' A novel mechanism for stopping inflammation - lessons from an ''old disease'' ' Professor Georg Schett

 

 

 

 

 

 

 

Guest Speaker: Professor Georg Schett

Institute for Clinical Immunology

University Erlangen-Nuremberg, Germany

 

Venue: David Shaw Lecture Theatre, Medical School

 

Date and time:  Tuesday 23^rd September 2014 at 1.00pm

 

Professor Schett will discuss:

 

“A novel mechanism for stopping inflammation - lessons from an “old disease”

 

 

2014 publications are below:

 

1.            Avouac J, Palumbo-Zerr K, Ruzehaji N, Tomcik M, Zerr P, Dees C, Distler A, Beyer C, Schneider H, Distler O et al: The nuclear receptor CAR / NR1I3 enhances the pro-fibrotic effects of TGF-beta and contributes to the development of experimental dermal fibrosis. Arthritis & rheumatology (Hoboken, NJ) 2014.

2.            Beyer C, Huang J, Beer J, Zhang Y, Palumbo-Zerr K, Zerr P, Distler A, Dees C, Maier C, Munoz L et al: Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Annals of the rheumatic diseases 2014.

3.            Beyer C, Zampetaki A, Lin NY, Kleyer A, Perricone C, Iagnocco A, Distler A, Langley SR, Gelse K, Sesselmann S et al: Signature of circulating microRNAs in osteoarthritis. Annals of the rheumatic diseases 2014.

4.            Beyer C, Zenzmaier C, Palumbo-Zerr K, Mancuso R, Distler A, Dees C, Zerr P, Huang J, Maier C, Pachowsky ML et al: Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling. Annals of the rheumatic diseases 2014.

5.            Boyle DL, Hammaker D, Edgar M, Zaiss MM, Teufel S, David JP, Schett G, Firestein GS: Differential roles of MAPK kinases MKK3 and MKK6 in osteoclastogenesis and bone loss. PloS one 2014, 9(1):e84818.

6.            Bozec A, Zaiss MM, Kagwiria R, Voll R, Rauh M, Chen Z, Mueller-Schmucker S, Kroczek RA, Heinzerling L, Moser M et al: T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Science translational medicine 2014, 6(235):235ra260.

7.            Conaghan PG, Kloppenburg M, Schett G, Bijlsma JW: Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee. Annals of the rheumatic diseases 2014, 73(8):1442-1445.

8.            D'Agostino MA, Boers M, Kirwan J, van der Heijde D, Ostergaard M, Schett G, Landewe RB, Maksymowych WP, Naredo E, Dougados M et al: Updating the OMERACT filter: implications for imaging and soluble biomarkers. The Journal of rheumatology 2014, 41(5):1016-1024.

9.            Dees C, Schlottmann I, Funke R, Distler A, Palumbo-Zerr K, Zerr P, Lin NY, Beyer C, Distler O, Schett G et al: The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Annals of the rheumatic diseases 2014, 73(6):1232-1239.

10.          Derer A, Groetsch B, Harre U, Bohm C, Towne J, Schett G, Frey S, Hueber AJ: Blockade of IL-36 Receptor Signaling Does Not Prevent from TNF-Induced Arthritis. PloS one 2014, 9(8):e101954.

11.          Distler A, Lang V, Del Vecchio T, Huang J, Zhang Y, Beyer C, Lin NY, Palumbo-Zerr K, Distler O, Schett G et al: Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Annals of the rheumatic diseases 2014, 73(6):1264-1268.

12.          Distler A, Ziemer C, Beyer C, Lin NY, Chen CW, Palumbo-Zerr K, Dees C, Weidemann A, Distler O, Schett G et al: Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. Annals of the rheumatic diseases 2014, 73(3):624-627.

13.          Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O et al: Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Annals of the rheumatic diseases 2014, 73(5):803-809.

14.          Finzel S, Sahinbegovic E, Ernet C, Kocijan R, Engelke K, Zwerina J, Englbrecht M, Schett G: Inflammatory bony spur formation in psoriatic arthritis is different from bony spur formation in hand osteoarthritis. Arthritis & rheumatology (Hoboken, NJ) 2014.

15.          Geusens P, Chapurlat R, Schett G, Ghasem-Zadeh A, Seeman E, de Jong J, van den Bergh J: High-resolution in vivo imaging of bone and joints: a window to microarchitecture. Nature reviews Rheumatology 2014, 10(5):304-313.

16.          Harre U, Kittan NA, Schett G: Autoantibody-mediated bone loss. Current osteoporosis reports 2014, 12(1):17-21.

17.          Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, Finzel S, Schett G: Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Annals of the rheumatic diseases 2014.

18.          Herz B, Albrecht A, Englbrecht M, Welsch GH, Uder M, Renner N, Schlechtweg P, Paul D, Lauer L, Engelke K et al: Osteitis and synovitis, but not bone erosion, is associated with proteoglycan loss and microstructure damage in the cartilage of patients with rheumatoid arthritis. Annals of the rheumatic diseases 2014, 73(6):1101-1106.

19.          Ipseiz N, Uderhardt S, Scholtysek C, Steffen M, Schabbauer G, Bozec A, Schett G, Kronke G: The nuclear receptor Nr4a1 mediates anti-inflammatory effects of apoptotic cells. Journal of immunology (Baltimore, Md : 1950) 2014, 192(10):4852-4858.

20.          Janko C, Filipovic M, Munoz LE, Schorn C, Schett G, Ivanovic-Burmazovic I, Herrmann M: Redox modulation of HMGB1-related signaling. Antioxidants & redox signaling 2014, 20(7):1075-1085.

21.          Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C et al: Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Annals of the rheumatic diseases 2014, 73(6):1020-1026.

22.          Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, Araujo E, Hueber AJ, Harre U, Engelke K et al: Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Annals of the rheumatic diseases 2014, 73(5):854-860.

23.          Kleyer A, Schett G: Arthritis and bone loss: a hen and egg story. Current opinion in rheumatology 2014, 26(1):80-84.

24.          Kocijan R, Finzel S, Englbrecht M, Engelke K, Rech J, Schett G: Decreased quantity and quality of the periarticular and nonperiarticular bone in patients with rheumatoid arthritis: a cross-sectional HR-pQCT study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2014, 29(4):1005-1014.

25.          Manger B, Schett G: Paraneoplastic syndromes in rheumatology. Nature reviews Rheumatology 2014.

26.          Manger B, Schett G: Palmar fasciitis and polyarthritis syndrome-Systematic literature review of 100 cases. Seminars in arthritis and rheumatism 2014, 44(1):105-111.

27.          Maueroder C, Munoz LE, Chaurio RA, Herrmann M, Schett G, Berens C: Tumor immunotherapy: lessons from autoimmunity. Frontiers in immunology 2014, 5:212.

28.          Maurer B, Graf N, Michel BA, Muller-Ladner U, Czirjak L, Denton CP, Tyndall A, Metzig C, Lanius V, Khanna D et al: Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Annals of the rheumatic diseases 2014.

29.          McGonagle D, Thomas RC, Schett G: Spondyloarthritis: may the force be with you? Annals of the rheumatic diseases 2014, 73(2):321-323.

30.          Museyko O, Marshall RP, Lu J, Hess A, Schett G, Amling M, Kalender WA, Engelke K: Registration of 2D histological sections with 3D micro-CT datasets from small animal vertebrae and tibiae. Computer methods in biomechanics and biomedical engineering 2014:1-16.

31.          Ossipova E, Cerqueira CF, Reed E, Kharlamova N, Israelsson L, Holmdahl R, Nandakumar KS, Engstrom M, Harre U, Schett G et al: Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint. Arthritis research & therapy 2014, 16(4):R167.

32.          Ruiz-Heiland G, Zhao Y, Derer A, Braun T, Engelke K, Neumann E, Mueller-Ladner U, Liu Y, Zwerina J, Schett G: Deletion of the receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia and bone damage in arthritis. Annals of the rheumatic diseases 2014, 73(4):771-779.

33.          Schauer C, Janko C, Munoz LE, Zhao Y, Kienhofer D, Frey B, Lell M, Manger B, Rech J, Naschberger E et al: Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nature medicine 2014, 20(5):511-517.

34.          Schett G: Bone formation in psoriatic arthritis: a report from the GRAPPA 2013 Annual Meeting. The Journal of rheumatology 2014, 41(6):1218-1219.

35.          Stadlmayr A, Aigner E, Huber-Schonauer U, Niederseer D, Zwerina J, Husar-Memmer E, Hohla F, Schett G, Patsch W, Datz C: Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta diabetologica 2014.

36.          Teufel S, Grotsch B, Luther J, Derer A, Schinke T, Amling M, Schett G, Mielenz D, David JP: Inhibition of bone remodeling in young mice by bisphosphonate displaces the plasma cell niche into the spleen. Journal of immunology (Baltimore, Md : 1950) 2014, 193(1):223-233.

37.          Timmen M, Hidding H, Wieskotter B, Baum W, Pap T, Raschke MJ, Schett G, Zwerina J, Stange R: Influence of antiTNF-alpha antibody treatment on fracture healing under chronic inflammation. BMC musculoskeletal disorders 2014, 15:184.

38.          Toh ML, Bonnefoy JY, Accart N, Cochin S, Pohle S, Haegel H, De Meyer M, Zemmour C, Preville X, Guillen C et al: A CSF-1 receptor monoclonal antibody has potent bone and cartilage protective effects in experimental arthritis. Arthritis & rheumatology (Hoboken, NJ) 2014.

39.          Tomcik M, Palumbo-Zerr K, Zerr P, Avouac J, Dees C, Sumova B, Distler A, Beyer C, Cerezo LA, Becvar R et al: S100A4 amplifies TGF-beta-induced fibroblast activation in systemic sclerosis. Annals of the rheumatic diseases 2014.

40.          Tomcik M, Zerr P, Pitkowski J, Palumbo-Zerr K, Avouac J, Distler O, Becvar R, Senolt L, Schett G, Distler JH: Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-beta signalling to prevent fibrosis. Annals of the rheumatic diseases 2014, 73(6):1215-1222.

41.          Topfer D, Finzel S, Museyko O, Schett G, Engelke K: Segmentation and quantification of bone erosions in high-resolution peripheral quantitative computed tomography datasets of the metacarpophalangeal joints of patients with rheumatoid arthritis. Rheumatology (Oxford, England) 2014, 53(1):65-71.

42.          Zerr P, Vollath S, Palumbo-Zerr K, Tomcik M, Huang J, Distler A, Beyer C, Dees C, Gela K, Distler O et al: Vitamin D receptor regulates TGF-beta signalling in systemic sclerosis. Annals of the rheumatic diseases 2014.

43.          Zhang Y, Dees C, Beyer C, Lin NY, Distler A, Zerr P, Palumbo K, Susok L, Kreuter A, Distler O et al: Inhibition of casein kinase II reduces TGFbeta induced fibroblast activation and ameliorates experimental fibrosis. Annals of the rheumatic diseases 2014.

44.          Zirngibl M, Furnrohr BG, Janko C, Munoz LE, Voll RE, Gregory CD, Schett G, Herrmann M: Loading of nuclear autoantigens prototypically recognized by SLE sera into late apoptotic vesicles requires intact microtubules and MLCK activity. Clinical and experimental immunology 2014.